ArticleProbiotics and antimicrobial proteins2026
Improving the Antimicrobial Activity of an Amyloidogenic Aβ Peptide Through Additional Fragments.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Given the similarities of action mechanism between amyloidogenic peptides (e.g. Aβ) and antimicrobial peptides (AMPs), we rationally engineered an amyloidogenic Aβ peptide to improve its antimicrobial activity: the aggregation-prone fragment was reverse-repeated to increase antimicrobial activity; poly-arginine (R) was flanked to both ends of the repeated fragments to enhance membrane interaction and inhibit amyloidogenesis; a β-turn fragment (DPDG/YNGK) was inserted between the repeated fragments to inhibit amyloidogenesis. Antimicrobial assays demonstrated that the designed peptides exhibited significantly enhanced antimicrobial activity. Among the designed peptides, Aβ-6R-YNGK, Aβ-6R-YNGK-r, Aβ-10R-YNGK, and Aβ-10R-YNGK-r exhibited potent antimicrobial activity, particularly against Staphylococcus epidermidis with MICs of 5, 5, 5, and 1 µM, respectively. Moreover, at 20 µM, these peptides showed significant anticancer activity and low cytotoxicity, reducing U937 human lymphoma cell viability to below 30% while maintaining over 80% viability of human microglial HMC3 cell. Our rational design approach provides a novel strategy for engineering antimicrobial peptide. The designed antimicrobial peptides Aβ-6R-YNGK, Aβ-6R-YNGK-r, Aβ-10R-YNGK, and Aβ-10R-YNGK-r hold promise as a new class of antimicrobial/cancer agents.
Indexed as
Identifiers
42671525What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.